Exosomes and osteosarcoma drug resistance.

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Osteosarcoma (OS) is a primary bone cancer with poor survival rates (<60%) due to multi-drug resistance and metastasis.
• Current treatments face challenges from OS multi-drug resistance, necessitating novel therapeutic approaches.
• Exosomes, small extracellular vesicles, are increasingly recognized for their roles in cancer progression and treatment resistance.

Purpose of the Study:

• To review the intricate relationship between exosomes and osteosarcoma chemotherapy resistance.
• To discuss the potential of exosomes in osteosarcoma diagnosis and treatment.
• To explore the future prospects of exosome-based nanomedicine for osteosarcoma therapy.

Main Methods:

• Literature review on exosome function in osteosarcoma.
• Analysis of exosome-mediated drug efflux mechanisms.
• Evaluation of exosomal contents (miRNA, proteins) in relation to drug resistance.
• Assessment of exosome-based nanocarrier applications in osteosarcoma treatment.

Main Results:

• Exosomes contribute to osteosarcoma chemotherapy resistance by facilitating drug efflux and transporting regulatory molecules.
• Exosomal miRNAs and proteins can influence the drug resistance of osteosarcoma cells.
• Exosomes serve as potential biomarkers for osteosarcoma diagnosis due to their ability to reflect parent cell characteristics.
• Exosomes exhibit properties suitable for nanomedicine, including targeted delivery and low toxicity, offering therapeutic potential.

Conclusions:

• Exosomes play a dual role in osteosarcoma, contributing to chemotherapy resistance while offering new avenues for diagnosis and treatment.
• Exosome-derived biomarkers and exosome-based nanocarriers represent promising strategies for improving osteosarcoma patient outcomes.
• Further research into the mechanisms of exosome-mediated chemoresistance is crucial for developing effective therapeutic interventions.